Enhanced immune effector cells and use thereof
US12173274B2 · kind B2 · utility
0Cited by
13References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2021 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | Sep 19, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/80
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.